The Ig superfamily protein PTGFRN coordinates survival signaling in glioblastoma multiforme

Brittany Aguila, Adina Brett Morris, Raffaella Spina, Eli Bar, Julie Schraner, Robert Vinkler, Jason W. Sohn, Scott Welford

Research output: Contribution to journalArticle

Abstract

Glioblastoma multiforme (GBM) is the most malignant primary brain tumor with a median survival of approximately 14 months. Despite aggressive treatment of surgical resection, chemotherapy and radiation therapy, only 3-5% of GBM patients survive more than 3 years. Contributing to this poor therapeutic response, it is believed that GBM contains both intrinsic and acquired mechanisms of resistance, including resistance to radiation therapy. In order to define novel mediators of radiation resistance, we conducted a functional knockdown screen, and identified the immunoglobulin superfamily protein, PTGFRN. In GBM, PTGFRN is found to be overexpressed and to correlate with poor survival. Reducing PTGFRN expression radiosensitizes GBM cells and potently decreases the rate of cell proliferation and tumor growth. Further, PTGFRN inhibition results in significant reduction of PI3K p110β and phosphorylated AKT, due to instability of p110β. Additionally, PTGFRN inhibition decreases nuclear p110β leading to decreased DNA damage sensing and DNA damage repair. Therefore overexpression of PTGFRN in glioblastoma promotes AKT-driven survival signaling and tumor growth, as well as increased DNA repair signaling. These findings suggest PTGFRN is a potential signaling hub for aggressiveness in GBM.

Original languageEnglish (US)
Pages (from-to)33-42
Number of pages10
JournalCancer letters
Volume462
DOIs
StatePublished - Oct 10 2019

Fingerprint

Glioblastoma
Survival
Proteins
DNA Repair
DNA Damage
Radiotherapy
Growth
Phosphatidylinositol 3-Kinases
Brain Neoplasms
Immunoglobulins
Neoplasms
Cell Proliferation
Radiation
Drug Therapy
Therapeutics

Keywords

  • AKT
  • Glioblastoma multiforme
  • PI3K p110β
  • PTGFRN
  • Radiation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The Ig superfamily protein PTGFRN coordinates survival signaling in glioblastoma multiforme. / Aguila, Brittany; Morris, Adina Brett; Spina, Raffaella; Bar, Eli; Schraner, Julie; Vinkler, Robert; Sohn, Jason W.; Welford, Scott.

In: Cancer letters, Vol. 462, 10.10.2019, p. 33-42.

Research output: Contribution to journalArticle

Aguila, B, Morris, AB, Spina, R, Bar, E, Schraner, J, Vinkler, R, Sohn, JW & Welford, S 2019, 'The Ig superfamily protein PTGFRN coordinates survival signaling in glioblastoma multiforme', Cancer letters, vol. 462, pp. 33-42. https://doi.org/10.1016/j.canlet.2019.07.018
Aguila, Brittany ; Morris, Adina Brett ; Spina, Raffaella ; Bar, Eli ; Schraner, Julie ; Vinkler, Robert ; Sohn, Jason W. ; Welford, Scott. / The Ig superfamily protein PTGFRN coordinates survival signaling in glioblastoma multiforme. In: Cancer letters. 2019 ; Vol. 462. pp. 33-42.
@article{5114154d7c9c4e0a9111cad395dd3345,
title = "The Ig superfamily protein PTGFRN coordinates survival signaling in glioblastoma multiforme",
abstract = "Glioblastoma multiforme (GBM) is the most malignant primary brain tumor with a median survival of approximately 14 months. Despite aggressive treatment of surgical resection, chemotherapy and radiation therapy, only 3-5{\%} of GBM patients survive more than 3 years. Contributing to this poor therapeutic response, it is believed that GBM contains both intrinsic and acquired mechanisms of resistance, including resistance to radiation therapy. In order to define novel mediators of radiation resistance, we conducted a functional knockdown screen, and identified the immunoglobulin superfamily protein, PTGFRN. In GBM, PTGFRN is found to be overexpressed and to correlate with poor survival. Reducing PTGFRN expression radiosensitizes GBM cells and potently decreases the rate of cell proliferation and tumor growth. Further, PTGFRN inhibition results in significant reduction of PI3K p110β and phosphorylated AKT, due to instability of p110β. Additionally, PTGFRN inhibition decreases nuclear p110β leading to decreased DNA damage sensing and DNA damage repair. Therefore overexpression of PTGFRN in glioblastoma promotes AKT-driven survival signaling and tumor growth, as well as increased DNA repair signaling. These findings suggest PTGFRN is a potential signaling hub for aggressiveness in GBM.",
keywords = "AKT, Glioblastoma multiforme, PI3K p110β, PTGFRN, Radiation",
author = "Brittany Aguila and Morris, {Adina Brett} and Raffaella Spina and Eli Bar and Julie Schraner and Robert Vinkler and Sohn, {Jason W.} and Scott Welford",
year = "2019",
month = "10",
day = "10",
doi = "10.1016/j.canlet.2019.07.018",
language = "English (US)",
volume = "462",
pages = "33--42",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - The Ig superfamily protein PTGFRN coordinates survival signaling in glioblastoma multiforme

AU - Aguila, Brittany

AU - Morris, Adina Brett

AU - Spina, Raffaella

AU - Bar, Eli

AU - Schraner, Julie

AU - Vinkler, Robert

AU - Sohn, Jason W.

AU - Welford, Scott

PY - 2019/10/10

Y1 - 2019/10/10

N2 - Glioblastoma multiforme (GBM) is the most malignant primary brain tumor with a median survival of approximately 14 months. Despite aggressive treatment of surgical resection, chemotherapy and radiation therapy, only 3-5% of GBM patients survive more than 3 years. Contributing to this poor therapeutic response, it is believed that GBM contains both intrinsic and acquired mechanisms of resistance, including resistance to radiation therapy. In order to define novel mediators of radiation resistance, we conducted a functional knockdown screen, and identified the immunoglobulin superfamily protein, PTGFRN. In GBM, PTGFRN is found to be overexpressed and to correlate with poor survival. Reducing PTGFRN expression radiosensitizes GBM cells and potently decreases the rate of cell proliferation and tumor growth. Further, PTGFRN inhibition results in significant reduction of PI3K p110β and phosphorylated AKT, due to instability of p110β. Additionally, PTGFRN inhibition decreases nuclear p110β leading to decreased DNA damage sensing and DNA damage repair. Therefore overexpression of PTGFRN in glioblastoma promotes AKT-driven survival signaling and tumor growth, as well as increased DNA repair signaling. These findings suggest PTGFRN is a potential signaling hub for aggressiveness in GBM.

AB - Glioblastoma multiforme (GBM) is the most malignant primary brain tumor with a median survival of approximately 14 months. Despite aggressive treatment of surgical resection, chemotherapy and radiation therapy, only 3-5% of GBM patients survive more than 3 years. Contributing to this poor therapeutic response, it is believed that GBM contains both intrinsic and acquired mechanisms of resistance, including resistance to radiation therapy. In order to define novel mediators of radiation resistance, we conducted a functional knockdown screen, and identified the immunoglobulin superfamily protein, PTGFRN. In GBM, PTGFRN is found to be overexpressed and to correlate with poor survival. Reducing PTGFRN expression radiosensitizes GBM cells and potently decreases the rate of cell proliferation and tumor growth. Further, PTGFRN inhibition results in significant reduction of PI3K p110β and phosphorylated AKT, due to instability of p110β. Additionally, PTGFRN inhibition decreases nuclear p110β leading to decreased DNA damage sensing and DNA damage repair. Therefore overexpression of PTGFRN in glioblastoma promotes AKT-driven survival signaling and tumor growth, as well as increased DNA repair signaling. These findings suggest PTGFRN is a potential signaling hub for aggressiveness in GBM.

KW - AKT

KW - Glioblastoma multiforme

KW - PI3K p110β

KW - PTGFRN

KW - Radiation

UR - http://www.scopus.com/inward/record.url?scp=85071704369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071704369&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2019.07.018

DO - 10.1016/j.canlet.2019.07.018

M3 - Article

VL - 462

SP - 33

EP - 42

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

ER -